12-month effectiveness and safety of VYC-17.5L for the treatment of moderate/severe nasolabial folds (NLFs

A Prospective, Open-Label, Observational, Postmarket Study Evaluating VYC-17.5L for the Correction of Moderate to Severe Nasolabial Folds Over 12 Months.

Article specifications

This clinical study was published in 2017 in journal of Dermatol Surg. (IF2014: 2.109) by British specialists. The aim of this study was evaluate 12-month effectiveness and safety of VYC-17.5L for the treatment of moderate/severe nasolabial folds (NLFs). Subjects ≥18 years old with moderate/severe NLFs were recruited (N = 70).

 

Results

Significant improvement was maintained in investigator-assessed NLF severity at 12 months, and investigators and subjects reported high satisfaction with VYC-17.5L throughout the study. VYC-17.5L is effective and well tolerated for the treatment of moderate to severe NLFs for 1 year.